SEC Form 4 · accession 0001209191-16-115782
FIVE PRIME THERAPEUTICS INC · FPRX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Franklin M Berger
Director
Period of report
Apr 22, 2016
Accepted (ET)
Apr 26, 2016 · 7:26 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001175505
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Apr 22, 2016 | P | 2,000 | $49.90 | A | 81,980 | D | |
| Common StockF2 | Apr 22, 2016 | P | 3,000 | $49.18 | A | 84,980 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $49.73 to $50.04, inclusive. The reporting person undertakes to provide to Five Prime Therapeutics, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes 2 and 3 to this Form 4.
- F2The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $49.045 to $49.31, inclusive.